Dermata Therapeutics Inc
NASDAQ:DRMA

  • LAST PRICE
    1.1500
  • TODAY'S CHANGE (%)
    -0.0100 (-0.8621%)
  • Bid / Lots
    1.1500/ 14
  • Ask / Lots
    1.2000/ 6
  • Open / Previous Close
    1.1800 / 1.1600
  • Day Range
    1.1000
    1.2400
  • 52 Week Range
    1.0501
    13.3500
  • Volume
    78,801

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
DRMA
Dermata Therapeutics Inc
1.7M
-0.1x
---
PBLA
Panbela Therapeutics Inc
1.7M
0.0x
---
KRBP
Kiromic Biopharma Inc
1.7M
-0.1x
---
ALLR
Allarity Therapeutics Inc
1.8M
0.0x
---
BJDX
Bluejay Diagnostics Inc
1.9M
0.0x
---
BTAX
Biostax Corp
1.9M
-1.2x
---
As of 2024-11-22

Company Information

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.

Contact Information

Headquarters
3525 Del Mar Heights Rd., #322SAN DIEGO, CA, United States 92130
Phone
858-223-0882
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Gerald Proehl
Chief Financial Officer, Senior Vice President
Kyri Van Hoose
Senior Vice President - Regulatory Affairs & Quality Assurance
Maria Bedoya Toro Munera
Senior Vice President, Chief Development Officer
Christopher Nardo
Lead Independent Director
David Hale

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.7M
Revenue (TTM)
$0.00
Shares Outstanding
1.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-13.37
Book Value
$24.25
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.